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Summary: The kinetics of myoglobin release after acute myocardial infarction were studied. Various algorithms
for calculation of infarct size, based on immunonephelometric determination of myoglobin and cumulative
myoglobin release into the circulation were compared. The cumulative myoglobin release and maximal serum
myoglobin concentration were compared with various measures of infarct size: cumulative release of creatine
kinase, electrocardiographic changes, and left ventricular ejection fraction. After acute myocardial infarction,
time to peak for myoglobin in serum was correlated with time to peak for creatine kinase (r = 0.645). On
average, the myoglobin concentration peaked 8.8 h earlier than creatine kinase activity. The rate of elimination
of myoglobin showed a large variation (0.041 —0.628 h"1) and was not correlated with the elimination rate
of creatine kinase. The elimination rate of myoglobin after acute myocardial infarction was shown to depend
on the patient's age and infarct size. The elimination constant of myoglobin is preferably estimated on an
individual basis in large and complicated infarctions. Cumulative myoglobin release correlated with algorithms
based on the cumulative release of creatine kinase (r = 0.622) and its isoenzyme MB (r = 0.660), and to a
lesser extent with the residual left ventricular ejection fraction (r = 0.513) and the sum of ST-segment
deviations on electrocardiography (r = 0.469). Maximal myoglobin values in serum correlated moderately
with the calculated infarct size (r = 0.488; based on creatine kinase-MB) and electrocardiographic changes
(r = 0.554). In combination with fast immunological methods for myoglobin determination, myoglobin peak
height offers the advantage of providing reliable results within 12 h after onset of symptoms. The method
based on cumulative myoglobin release is an equivalent alternative; it also requires a limited number of
consecutive determinations of myoglobin in serum, but yields results only after 36 h. As is the case for methods
based on cumulative enzyme release, the proposed algorithms cannot be used if concomitant skeletal muscle
damage has also occurred.
Introduction
 Λ Λ . . , . . , .
number οι sophisticated non-invasive techniques have
The prognosis of acute myocardial infarction is been proposed, such as electrocardiographic mapping
largely determined by infarct size (1). Infarct size can techniques (3), nuclear scintigraphy (4), and nuclear
further be used as a measure for studying effects of magnetic resonance (5). Infarct size can also be de-
thrombolytic therapy in acute myocardial infarction termined from the appearance of cardiac enzymes1)
(2). In clinical practice, calculation of infarct size in (creatine kinase, α-hydroxybutyrate dehydrogenase1)).
patients however remains cumbersome. In the past, a in serum following infarction (2, 6). However, because
of the relatively slow elimination rate of cardiac en-
1
 Enzymes: zymes from plasma, the minimal duration of the in-
Creatme kinase (ATP: Creatine N-Phosphotransferase; EC
 tegration period necessary for calculating infarct size
a-Hydioxy butyrate dehydrogenase ([S]-3-Hydroxybutan- bY these methods ranges from two to seven days,
oate:NAD+-oxidoreductase; EC 1.1.1.27) depending on the enzyme chosen. Myoglobin, a mus-
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cle protein of MT17 700 is rapidly released into serum
after acute myocardial infarction and can be used for
its diagnosis (7, 8). In contrast to cardiac enzymes,
myoglobin disappears relatively rapidly from the
plasma compartment and is partly excreted in the
urine (9). Potential interference from the release of
acute myocardial infarction marker molecules from
damaged skeletal muscle during a further stay in
hospital can be minimized by choosing marker mol-
ecules characterized by a relatively short appearance
in the plasma. The recent availability of reliable, fast
immunological assays for measuring serum myoglo-
bin in the emergency laboratory has created new
possibilities for the estimation of infarct size within
36 h after onset of symptoms (10, 11). In the present
work, we studied the kinetics of myoglobin release
after myocardial infarction. Maximal myoglobin con-
centration in serum and the cumulative release of
myoglobin were compared with the cumulative release
of creatine kinase and its MB isoenzyme after acute
myocardial infarction. Furthermore, we evaluated the
possibilities of using peak myoglobin values and serial
myoglobin measurements in serum for infarct sizing
within 36 h after onset of symptoms. Infarct sizes
calculated by cumulative myoglobin release were com-
pared with electrocardiographic findings. As the pro-
gnosis of acute myocardial infarction can be predicted
by both infarct size and the left ventricular ejection
fraction (12), we also compared this cumulative myo-
globin release with the residual left ventricular ejection
fraction.
Materials and Methods
Patients
Thirty two acute myocardial infarction patients (21 males: mean
age ± 65.4 ± 12.3 years; body weight: 71.8 ± 10.7 kg; 11
females: mean age: 60.7 ± 15.3 years, body weight: 67.0 ± 5.8
kg) were diagnosed acute myocardial infarction according to
the WHO criteria (13). The mean time interval between onset
of symptoms and hospital admission was 185 ±170 min.
Twenty seven patients (84%) with acute myocardial infarction
received thrombolytic therapy, 30 U anistreplase, administered
intravenously. Five other patients did not receive thrombolytic
therapy because of medical contraindications (14). Blood was
sampled immediately on admission, then every 4 h during the
first 48 h of hospitalization. Upon admission, serum creatinine
concentrations for males and females were 75 ± 17 umol/1 and
61 + 14 μηιοΐ/ΐ. None of the acute myocardial infarction patients
showed clinical signs of preexisting renal insufficiency.
Analytical methods
Serum creatine kinase activity was assayed at 37 °C according
to IFCC (15), using commercially available reagents (Boehrin-
ger Mannheim, Germany) on a Hitachi 717 analyser (Hitachi,
Tokyo, Japan). Serum creatine kinase-MB activity was assayed
at 37 °C on an aca analyzer (DuPont, Wilminton, DE 19898).
Serum myoglobin and myoglobin in tissue extracts was assayed
using an immunonephelometric assay (inter-assay CV: 6%) on
a BNA nephelometer (Behringwerke, Marburg, Germany) (10).
Serum creatinine was measured enzymatically (16) on a Hitachi
717 anlayser.
Infarct size, based on a standard 12 lead electrocardiogram was
calculated using the sum of all ST-segment deviations obtained
at the moment of maximal repolarisation disturbances (17). In
14 acute myocardial infarction patients (43%), infarct size could
not be estimated using electrocardiographic data because of
uninterpretable patterns. Infarct size based on the use of cu-
mulative creatine kinase and creatine kinase-MB activity in
serum was calculated according to Roberts (6). Individualized
elimination constants (kd) were determined by fitting serum
creatine kinase and creatine kinase-MB activities in the decline
part of the time-activity curves into a first-order equation:
A = AO e~kd'1, in which A represents serum enzyme activity at
time t, and A0 the enzyme activity at time t = 0.
Heart tissue was obtained at autopsy from acute myocardial
infarction patients without other pre-existing myocardial dis-
ease. Samples were taken in a homogeneous section of normal
(n = 5) and infarcted (n = 5) myocardium. Tissue extracts were
prepared according to Tsung (18). The left ventricular ejection
fraction was determined during the second week of hospitali-
zation using echocardiography (19).
Compartment model describing quanti tat ive release
of myoglobin after acute myocardial infarction
In order to describe myoglobin kinetics after acute myocardial
infarction, a compartment model was developed. In this model,
the infarcted zone and the plasma pool are considered as
different compartments. Animal models showed little differ-
ences in myoglobin kinetics between one- and two-compartment
models (20). The biexponential character of iodine-labelled
myoglobin washout curves, however, may reflect recirculating
radioactive fragments of the parent molecule rather than true
two-compartment kinetics of the parent molecule (20). Since a
one-compartment model requires fewer measuring points for
calculating cumulative myoglobin results, we used a one com-
partment model for routine clinical purposes. The myoglobin
concentration in the human myocardium is about 110 nmol/g
wet weight (9). After acute myocardial infarction, leakage of
molecules occurs due to the faulty regulation of transmembra-
neous concentration gradients (21). Our experiments demon-
strated relative losses of more than 65% of the initial myoglobin
content of the infarcted zone, corresponding to an average
myoglobin loss of 73 +15 nmol/g wet weight. After being
released into the plasma, myoglobin is catabolized in the kidney
(22). Otherwise, as long as plasma myoglobin concentrations
exceed renal threshold values, myoglobin is partly excreted in
the urine. In patients, renal threshold values for myoglobin
have been reported to be 280 to 850 nmol/1 (9). As maximal
myoglobinaemia in acute myocardial infarction is between 6
and 250 nmol/1, the loss of myoglobin in the urine can be
quantitatively neglected.
Cumulative myoglobin release and infarct size
When using cumulative release as a model for estimating infarct
size, inter-individual variations of post-acute myocardial in-
farction myoglobin kinetics must be taken into account. Math-
ematically, cumulative myoglobin release during a time interval
0-T can be estimated according to the following equation (6):
Cumulative myoglobin release
Mbr = kd · \ Mb(0df (Eq. 1)
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in which Mb(i) represents the myoglobin concentration in
serum at sampling time t, and kd the elimination constant for
myoglobin in serum. The elimination constant was calculated
from serially determined myoglobin concentrations after the
myoglobin concentration had passed its peak, and during the
time interval between 80% of the maximal myoglobin concen-
tration and the moment that myoglobin concentrations were
twice the upper reference range. In the presence of renal dys-
function or heart failure, and in cases of extended tissue injury,
the haemodynamics are not always stable, and may show an
unpredictable prolongation of the elimination rate (20). As the
kd for myoglobin shows variations, the effects of kd variation
on the determination of infarct size were studied by comparing
algorithms using a fixed kd value with algorithms using an
individualized kd value. In order to calculate infarct size, a
proportionality constant K is introduced (6):
K = D · [PMb · (MbN - Mb,)]-1,
in which MbN represents the myoglobin concentration in nor-
mal myocardium, Mbi the myoglobin concentration in myo-
cardium undergoing homogeneous infarction, D the volume
into which myoglobin released from the heart is distributed,
and PMb the proportion of myoglobin released into the blood
compared with myoglobin depleted from the heart. One gram
myoglobin equivalent is defined as the amount of ischemic
myocardium releasing myoglobin into the circulation equivalent
to the amount released by 1 gram of myocardium undergoing
homogeneous infarction. In the present study, we prefer a PMb-
value of 0.15 as a compromise between direct efflux of the
marker molecule and its post-acute myocardial infarction de-
gradation. In experimental dog models, total recovery of myo-
globin from infarcted zones is only observed in larger infarc-
tions (total myoglobin release > 70 mg) (20). Furthermore, in
vitro stability of myoglobin at physiological temperature over
a 24 h period is about 20% (23). Finally, infarct size (g myo-
globin equivalent) is obtained by taking into account the pa-
tient's body weight (kg). In view of the important variation in
body weight in acute myocardial infarction patients (CV values
of 15% (males) and 8% (females)), this quantity needs to be
individualized: infarct size = K · Mbr · BW.
Practical calculation of infarct size
In clinical practice, only a finite number of data on myoglobin
concentration can be obtained. Infarct size was calculated from
N consecutive myoglobin determinations as follows:
Tab. 1. Typical values for the different variables in the calcu-
lation of infarct size from cumulative myoglobin release
Variable1) Typical value
Cumulative myoglobin release
Mbr = Mb(tN) (Eq.2)
in which Mb(tN) represents the last myoglobin concentration
of the observation period, Mbj the mean myoglobin concentra-
tion between two consecutive measurements after subtraction
of the baseline concentration for serum myoglobin, and Atj the
time interval between two measurements.
With a median time interval of 8 h between onset of symptoms
and the myoglobin peak, and a kd ranging from 0.041 h"1 to
0.628 h"1, the time needed to restore myoglobin concentrations
to twice the baseline level in uncomplicated acute myocardial
infarction was 30.2 ± 0.9 h after onset of symptoms. The sum-
mation interval for myoglobin release was chosen as 36 h
(n = 19) or the time taken for serum myoglobin values to
decrease to 3.4 nmol/1 (n = 13). Prolonged integration may
lead to overestimation, because myoglobin may be released for
other reasons. In the rare acute myocardial infarction case
(1/32) where myoglobin release occurred in two waves (due to
discontinuity of infarction or the occurrence of reinfarction),
both waves were sized independently. The intermediate minimal
MbN — Mbi, nmol/g wet weight
D, ml/kg body weight
K, g myoglobin equivalent-ml/nmol-kg
T, h
Baseline serum myoglobin
concentration, nmol/1
73
0.127
44
0.15
4
36
MbN, tissular myoglobin concentration; Mbi, myoglobin
concentration in the infarcted myocardium; kd, elimination
constant; D, distribution volume; K, proportionality con-
stant; PMb, proportion of immunoreactive myoglobin re-
leased into blood compared with myoglobin depleted from
the heart; T, integration time interval.
serum myoglobin concentration was used as the cut-off point
between the two integration periods. Table 1 summarizes the
values for the variables used in the algorithm for calculation
of infarct size.
Statistics
Results were expressed as mean and standard deviation. Statis-
tical analysis was performed using non-parametric methods.
Differences between groups were evaluated using two-tailed
Mann-Whitney U test. Correlation analysis was performed by
means of the Pearson correlation test.
Results
Appearance of myoglobin into the circula-
tion after acute myocardial infarction
In acute myocardial infarction patients, repetitive
serum samples were taken in order to study the ki-
netics of creatine kinase and myoglobin release after
acute myocardial infarction. In 31 patients, one single
myoglobin peak was observed. In one patient, a sec-
ondary myoglobin peak was observed 37 h after onset
of symptoms. The median time interval between onset
of symptoms and maximal myoglobin concentration
in serum was 8 h (range 3—20 h). Thrombolytic treat-
ment had no significant effect on the time to peak:
7.5 ± 2.9 h (non-thrombolysis group) vs. 8.0 ± 4.0 h,
which is in agreement with the results obtained for
creatine kinase-MB (19.2 + 7.0 h vs 16.7 ± 5.9 h,
respectively). Time to peak for myoglobin correlated
moderately with time to peak for creatine kinase: y
(time to peak for myoglobin, h) = 0.395 χ (time to
peak for creatine kinase, h) + 1.379, r = 0.645,
Syx = 2.852. On average, peaks for myoglobin in
serum preceded those for creatine kinase by 8.8
+ 4.6 h (fig. 1).
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Fig. 1. Comparison between time to peak for creatine kinase
(x-axis, h) and myoglobin (y-axis, h) after acute my-
ocardial infarction. The equation for the correlation:
y = 0.395x + 1.379 (r = 0.645, η = 32, Syx = 2.852).
Elimination of myoglobin from the circula-
tion after acute myocardial infarction
Calculated kd values for myoglobin showed a large
variation (median: 0.127h"1; range: 0.041 —
0.628h"1). In males, the median kd for myoglobin
was found to be 0.128h"1 (range 0.041h"1-
0.270 h"1), with comparable values in females (me-
dian 0.107h"1; range 0.041 h"1-0.628 h"1). The
highest kd values (0.410 h"1-0.628 h"1) were ob-
tained in two cases who needed cardiopulmonary
resuscitation during the acute phase. The elimination
rate of myoglobin was not correlated with infarct size,
as calculated by cumulative creatine kinase-MB re-
lease: y (fcd, h"1) = —3.44 10"2x (log infarct size,
g creatine kinase-MB equivalent) + 0.186
(r = -0.177, n = 29, Syx = 0.069). Elimination con-
stants of myoglobin in anterior infarctions (0.110
± 0.061 h"1; n = 12) were comparable to those of
inferior infarctions (0.144 ± 0.071 h"1; n = 16). In
the group of patients where thrombolytic therapy was
contraindicated (n = 5), the median kd value was
0.134h"1 (range: 0.055-0.249h"1), which was not
significantly different from the thrombolysis group.
Maximal serum myoglobin concentrations (median:
33.3 nmol/1; range: 7-320 nmol/1) were reached
3 — 20 h (median 8h) after onset of symptoms. The
myoglobin elimination constant was negatively cor-
related (p < 0.05) with patient age: y (elimination
constant, h"1) = —2.69 10"3x (patient's age, years)
+ 0.314 (r = -0.505, n = 30, Syx = 0.06). Table 3
summarizes the distribution of the elimination con-
stant of myoglobin according to age. The effect of
the initial serum creatinine concentration on kd values
for myoglobin, was, however negligible.
Correlations between maximal serum myo-
globin concentration, cumulative myoglobin
and enzyme release, and other indices of in-
farct size
Table 2 shows the individual data on creatine kinase-
MB and myoglobin kinetics, together with the infarct
size based on serial creatine kinase-MB and myoglo-
bin release. Maximum myoglobin serum concentra-
tions correlated well with cumulative myoglobin re-
lease: log(y) (maximal myoglobin concentration,
nmol/1) = 0.793 log(x) (infarct size, g myoglobin
equivalent) + 0.569 (r = 0.837, n = 29, Syx = 0.254).
Cumulative myoglobin release correlated well with
cumulative release of creatine kinase: log(y) (infarct
size, g myoglobin equivalent) = 0.993 log(x) (infarct
size, g creatine kinase equivlanet) —0.254, r = 0.622,
n = 29, Syx = 0.383. Correlation with the heart-spe-
cific creatine kinase-MB isoenzyme was comparable:
log(y) (infarct size, g myoglobin equivalent) = 0.862
log(x) (infarct size, g creatine kinase-MB equivalent)
+ 0.146, r = 0.660, n = 29, Syx = 0.374. The latter
correlation coefficient was not statistically different
from the one obtained between myoglobin-peak and
cumulative creatine kinase-MB release (tab. 3). Figure
2 illustrates the correlation between infarct size cal-
culated by cumulative myoglobin release and by cu-
mulative creatine kinase-MB activity. Elimination
constants for myoglobin and creatine kinase after
acute myocardial infarction, however, did not corre-
¥ I02r
c
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Infarction size creatine kinase MB [g equivalent]
Fig. 2. Comparison between calculated infarct size based on
cumulative release of creatine kinase-MB (x-axis, g crea-
tine kinase-MB equivalent) and myoglobin (y-axis,
g myoglobin equivalent) using individualized values
for kd. The unit of infarction size as calculated by our
proposed method is an artificial unit obtained after
calculations and after comparison with healthy my-
ocardial tissue, therefore termed g equivalent. The same
procedure has been done earlier by the group of Roberts
et al. (6). The equation for the correlation:
log(y) = 0.862 log(x) + 0.146 (r = 0.660, n = 29,
Syx = 0.374).
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Tab. 2. Individual data of acute myocardial infarction patients
Patient
no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Thrombo-
lysis
(Yes/No)
No
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Time to peak
creatine
kinase-MB
(h)
18
13
28
11
12.5
21
19
14
18
7
14
12
13
17
19
10
24
13.5
16
15
32
16
15.5
14
24
15
24
18
10.5
15
32
myoglobin
(h)
10
7
3
4
4.5
11
8
7
8
4
7.5
4.5
5
8
4
6.5
8
6
8
12
16
10
6
8
7
6
12
11
3.5
12
20
Peak value
creatine
kinase-MB
(U/l)
87
73
368
145
138
229
95
59
71
76
27
111
87
71
51
210
176
204
90
31
175
165
150
320
296
735
79
115
100
221
175
myoglobin
(nmol/1)
40.0
17.7
173
84.2
320
196
39.1
9.2
45.8
13.9
20.5
89
33.3
12
31.8
24
270
110
32
7
42.3
17
8
94.3
51.6
88.8
64
18.1
28
10
17.8
Infarct size1)
creatine
kinase-MB
(g creatine
kinase-MB eq)
22.9
17.1
40.0
24
18
37
17
14
21
11.5
8
22
16
9
10
14
45
60
12
2
23
60
19
37
15
91
37
11
13
38
15
myoglobin
(g myoglobin
eq)
29
18.9
28.0
31.8
70
82
19.2
5
10
10
9
51
16
3
8
3
70
39
24
2
19
32
4
36
33
94
29
9
10
4
6
!) Data based on individualized kd values
Tab. 3. Distribution of elimination constant of myoglobin in
acute myocardial infarction patients according to age
Age group, years
Under 50
51-70
Over 70
n1)
5
12
13
Median (range), h l
0.224 (0.127-0.270)*
0.110 (0.041-0.210)
0.107 (0.055-0.249)
') The two female patients who needed intensive resuscitation
procedures, which caused considerable skeletal muscle dam-
age, were excluded.
* p < 0.05 Mann- Whitney U-test for difference with the acute
myocardial infarction patients aged over 70.
late: y(myoglobin-/:d, h l ) = 0.342x (creatine kinase-
fcd, h-1) + 0.125, r = 0.077, η = 29, Syx = 0.070.
Correlations between measures of myoglobin release
and other indices of infarct size are summarized in
table 4. A moderate correlation was obtained with
infarct size calculated using a standard 12-lead elec-
trocardiography: log(y) (infarct size, g myoglobin
equivalent) = 0.389x (sum of ST-deviations, mV)
+ 0.857, r = 0.470, n = 18, Syx = 0.424. The corre-
lation coefficient between electrocardiogram and
myoglobin release is comparable to the one obtained
between electrocardiogram and creatine kinase-MB
release: log(y) (infarct size, g creatine kinase-MB
equivalent) = 0.323x (sum of ST-deviations, mV)
+ 1.07, r = 0.628, n = 18, Syx = 0.23.
Effects of body weight and kd variation on infarct
size results were studied: for males and females, CVs
of body weight distribution were 15% and 8%, re-
spectively. Variation of kd was more important, with
CVs of 46% (males) and 63% (females). Infarct size
calculated by cumulative myoglobin release was in-
versely proportional to the residual ventricular func-
tion, as expressed by the left ventricular ejection frac-
tion: y (log(infarct size), g myoglobin equivalent)
= 15.13 (1/x) (left ventricular ejection fraction, %)
+ 0.885, r = 0.513, n = 15, Syx = 0.490.
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Tab. 4. Correlation between quantities of myoglobin release and other indicators of infarct size
Infarct size based on cumulative
creatine kinase-MB release,
g creatine kinase-MB equivalent
(n = 29)
Infarct size based on
electrocardiograph^ findings, mV
(n = 18)
Maximum myoglobin concentration,
nmol/1
Cumulative myoglobin release, g myo-
globin equivalent
fixed1) kd
individualized ka
log(y) = 0.6261og(x) + 0.738
r = 0.488, S^ = 0.407
log(y) = 0.7631og(x) - 0.260
r = 0.435, S^ = 0.561
log(y) = 0.8621og(x) + 0.146
r = 0.660, Syx = 0.374
log(y) = 0.747x - 0.394
r = 0.554, S^ = 0.503
log(y) = 0.579x + 0.702
r = 0.530, Sy, = 0.530
log(y) = 0.389x + 0.857
r = 0.470, Syx = 0.424
') kd: 0.127
Discussion
After acute myocardial infarction, the kinetics of
myoglobin show large interindividual variations. The
rate of appearance of myoglobin in the plasma cor-
relates with the rate of appearance of creatine kinase.
The effect of the pre-infarction glomerular filtration
rate on the apparent myoglobin elimination rate dur-
ing acute myocardial infarction is negligible. Patient's
age correlates negatively with the apparent elimina-
tion rate of myoglobin from plasma, which can be
explained by a decreased capacity of the kidney tissue
to eliminate myoglobin from the plasma compartment
•upon ageing. These findings are in agreement with
the increase of serum myoglobin reference values with
age (11). Previously, Roe et al. (24) demonstrated in
dogs that individualisation of kd data did not improve
the estimation of infarct size. However, data from
post-acute myocardial infarction creatine kinase ki-
netics in the dog model cannot be directly translated
into human post-acute myocardial infarction myo-
globin kinetics, due to the difference in physiological
background in the release of myoglobin vs creatine
kinase molecules from damaged myocardium (21).
Moreover, different mechanisms operate in the elim-
ination of myoglobin and creatine kinase molecules
from the circulation. As the plasma half-life of myo-
globin shows a considerable variation after infarction,
an individualized estimation of the elimination con-
stant is preferable for calculating the cumulative
myoglobin release from serum myoglobin determi-
nations, particularly in patients with large and com-
plicated infarctions.
Maximal myoglobin values in serum correlate well
with cumulative myoglobin release and infarct sizes
calculated by cumulative creatine kinase-MB release
and electrocardiography. These results are in agree-
ment with earlier work involving non-thrombolysed
infarctions (25).
In combination with fast quantitative myoglobin
measurements (10, 11), the algorithm based on cu-
mulative myoglobin release allows a relatively simple
estimation of infarct size within 36 h after onset of
symptoms, which is significantly shorter than the in-
tegration periods used in the methods based on cu-
mulative release of cardiac enzymes (2, 6). This is
advantageous in cases of muscle trauma, or reinfarc-
tion occurring from the second day of hospitalization
onwards. From a theoretical point of view, the largest
source of calculation errors potentially arises from
uncertainty in estimating the myoglobin elimation
rate, which is significantly faster than that for the
majority of cardiac enzymes (26). Therefore, to obtain
reliable sizing results, multiple myoglobin determi-
nations in serum during the elimination phase are
preferable.
In humans, cumulative myoglobin release is largely
determined by the down-hill part of the curve (8 — 36 h
after onset of symptoms). Thus, considerable post-
acute myocardial infarction losses of immunoreactive
myoglobin occur between its myocardial release and
the prelevation of serum samples. A good correlation
was obtained between sizing results obtained by cu-
mulative myoglobin release and the results obtained
by the method of Roberts (6). The method described
allows much simpler calculations in comparison with
the sizing algorithms proposed by Groth (27 — 29).
Furthermore, changes in myoglobin elimination rate
induced by age are taken into account and secondary
myoglobin peaks (staccato phenomenon, (30)) can be
quantified. Although results obtained with non-indi-
vidualized kd do not differ significantly from the re-
sults using individualized kd values, differences may
be considerable in certain cases. Values obtained by
calculation of cumulative myoglobin release are gen-
erally lower than those obtained by cumulative release
of creatine kinase or creatine kinase-MB. This can be
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 12
Delanghe et al: Acute myocardial infarction size and myoglobin release 829
explained by the faster kinetics of myoglobin, which
induce a larger relative difference between the area
under the curve, as calculated for the ideal situation
(Eq. (1)) and the clinical approximation (Eq. (2)). The
use of a one compartment model can lead to a small
underestimation of infarct size (20). Moreover, cu-
mulative activity measurements of cardiac enzymes
may overestimate the actual infarct size, because of
post-synthetic changes occurring after enzyme release
from the myocardium, which lead to rapid loss of
specific activity (31). Methods based on cumulative
enzyme activity measurements overestimate infarct
size after reperfusion (32).
In contrast to methods based on 12-lead electrocar-
diography or nuclear scintigraphy, the results ob-
tained by cumulative myoglobin release are not influ-
enced by infarct localization. Particularly, infarctions
involving the posterior wall are difficult to diagnose,
as none of the standard leads directly interrogates
this region (33). In non-Q wave infarctions, nuclear
scintigraphy is an insensitive test for detecting acute
myocardial infarction (34). Infarct sizes calculated by
the proposed algorithm correlated moderately with
the residual left ventricular ejection fraction, which is
known to be a prognostic factor, related to infarction
size (35).
If the acute myocardial infarction is accompanied by
significant skeletal muscle damage during the early
phases (e. g. intramuscular injections, cardio-pulmo-
nary resuscitation), the proposed sizing method de-
scribed cannot be used, because of concomitant re-
lease of myoglobin from skeletal muscle (typical tissue
myoglobin content: 200 to 250 nmol/g wet weight),
resulting in a significant overestimation of infarct size.
However, this problem is also encountered when using
cardiac enzymes as marker molecules, because skeletal
muscle contains large quantities of "cardiac" enzymes.
When infarct size is calculated from the results of
other immuno-assays for myoglobin (RIA, ELISA),
the values for MbN and Mbi may differ, because the
results for heart tissue myoglobin are assay-dependent
(10).
We compared algorithms for calculating infarct size
based on post-acute myocardial infarction myoglobin
release. In contrast to former RIA methods, the fast
imimmonephelometric and immunoturbidimetric as-
says produce quick results, available on a 24 h basis.
Infarct size obtained by myoglobin peak height allows
a first approximation of infarct size within 12 h. Re-
sults based upon cumulative myoglobin release give
data comparable to those based on cumulative crea-
tine kinase or creatine kinase-MB release, but are
only available after 30 to 36 h. Whether the estimation
of infarct size one or two days earlier is clinically
relevant remains to be proven in further studies. How-
ever, the shorter integration interval needed for myo-
globin protects against errors due to non-cardiac en-
zyme release from the 36th hour onwards. Indivi-
dualisation of the elimination constant is preferable
for calculating cumulative myoglobin release, partic-
ularly in patients with large and complicated infarc-
tions.
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